Methotrexate is a folate antimetabolite chemical used to treat many forms of cancer and cleared mainly by kidney which result in a nephrotoxicity as a major complication of methotrexate. Trivalent chromium complex, chromium picolinate (CrPic), is mostly utilized to regulate glucose and raise insulin sensitivity—particularly in diabetes. The objective of this study was to assess the renoprotective effects of Chromium in mitigating nephrotoxicity induced by Methotrexate in rats. Study conducted on 32 male rats divided into 4 groups; Group I (Control group) in which rats received distilled water orally for 8 days, Group II (Induction group) which received a single intraperitoneal injection of Methotrexate (20 mg/kg) on the first day Followed by distilled water for 7 days, Group III (Chromium 2mg) which received a single intraperitoneal injection of Methotrexate (20 mg/kg) on the first day Followed by CrPic at a dose (2mg/kg) orally for 7 days and finally group IV which is similar to Group III except that the dose of CrPic is 4mg/kg. The levels of creatinine, Kidney Injury Molecule-1 (KIM-1), interleukin 1 beta (IL-1β), and tumor necrosis factors-α (TNF-α) were evaluated for all studied groups and the results showed that the administration of CrPic caused a significant decrease (p
